Finance

Lists
Q3 2026 earnings • released • EPS beat +191.53% • Revenue beat +0.55%
See results
TEM:NASDAQ
Tempus AI Inc
$78.48
+8.67%
(+6.26) 1D
$77.90
-0.74% (-0.58)
After hours
Closed: Nov 2, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEM...
Open
$74.43
High
$83.42
Low
$70.30
Mkt. cap
14.30B
Avg. vol.
6.50M
Volume
17.03M
52-wk high
$90.50
52-wk low
$40.77
EPS
-$1.43
Shares outstanding
177.20M
No. of employees
4K
Open
$74.43
High
$83.42
Low
$70.30
Mkt. cap
14.30B
Avg. vol.
6.50M
Volume
17.03M
52-wk high
$90.50
52-wk low
$40.77
EPS
-$1.43
Shares outstanding
177.20M
No. of employees
4K
News stories
From web sources and news partners
Profile
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM." Wikipedia
About Tempus AI Inc
CEOEric Lefkofsky
Employees3.8K
Founded2015
HeadquartersChicago, Illinois, United States
SectorHealth care
Websitetempus.com
Analyst ratings
Based on 13 analysts giving stock ratings to TEM in the past 3 months
Buy
Buy
6
Hold
7
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for TEM in the last 3 months.
Highest
Current $78.48
$95.00 (+21.05%)
Average
$74.69 (-4.83%)
Lowest
$50.00 (-36.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tycho Peterson
Jefferies
Hold
Upgraded
$70.00
-10.8%
11/02/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$68.00
-13.4%
10/26/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
$70.00
-10.8%
10/14/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
$95.00
+21%
10/12/2026
Lu Li
Bank of America Securities
Hold
Maintained
$75.00
-4.4%
10/09/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
$75.00
-4.4%
10/09/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$92.00
+17.2%
10/01/2026
Evie Koslosky
Goldman Sachs
Hold
Initiated
$75.00
-4.4%
09/22/2026
Unknown Analyst
UBS
Hold
Initiated
$70.00
-10.8%
09/08/2026
Doug Schenkel
UBS
Hold
Initiated
$70.00
-10.8%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Hold
Initiated
$67.00
-14.6%
09/08/2026
Sarah James
Cantor Fitzgerald
Buy
Initiated
$80.00
+1.9%
09/02/2026
David Westenberg
Piper Sandler
Buy
Upgraded
$76.00
-3.2%
09/01/2026
Eugene Mannheimer
Freedom Capital Markets
Hold
Maintained
$73.00
-7%
08/31/2026
Mark Massaro
BTIG
Buy
Maintained
$80.00
+1.9%
08/20/2026
Daniel Arias
Stifel Nicolaus
Hold
Maintained
$50.00
-36.3%
08/03/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$59.00
-24.8%
07/31/2026
Matt Larew
William Blair
Hold
Reiterated
-
-
07/31/2026
Ryan MacDonald
Needham
Buy
Reiterated
$75.00
-4.4%
07/31/2026
Daniel Brennan
TD Cowen
Buy
Maintained
$71.00
-9.5%
07/15/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$70.00
-10.8%
07/10/2026
Paige Chamberlain‏
Wolfe Research
Hold
Initiated
-
-
06/01/2026
Unknown Analyst
Wolfe Research
Hold
Initiated
-
-
06/01/2026
Andrew Brackmann
William Blair
Hold
Reiterated
-
-
06/01/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$100.00
+27.4%
04/13/2026
Last report
Just released
Today, 8:45 AM
Fiscal period
Q3 2026
$0.07 / -$0.08
+191.53%beat
Revenue / Est. (USD)
411.54M / 409.30M
+0.55%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
334.21M
367.21M
348.12M
382.49M
Cost of goods sold
124.26M
129.50M
126.08M
135.99M
Cost of revenue
124.26M
129.50M
126.08M
135.99M
Research and development expenses
83.05M
90.62M
94.16M
96.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
187.39M
208.41M
212.60M
224.86M
Operating expense
270.44M
299.03M
306.76M
321.42M
Total operating expenses
394.70M
428.52M
432.83M
457.41M
Operating income
-60.50M
-61.31M
-84.72M
-74.92M
Other non operating income
3.88M
2.83M
4.60M
4.28M
EBT including unusual items
-79.71M
-60.16M
-125.98M
5.95M
EBT excluding unusual items
-65.90M
-71.80M
-93.68M
-79.89M
Income tax expense
276.00K
-5.99M
-62.00K
309.00K
Effective tax rate
-0.35%
9.96%
0.05%
5.19%
Other operating expenses
-
-
-
-
Net income
-79.98M
-54.17M
-125.92M
5.64M
Net profit margin
-23.93%
-14.75%
-36.17%
1.48%
Earnings per share
-0.11
-0.04
-0.13
-0.04
Interest and investment income
4.60M
5.12M
3.87M
3.90M
Interest expense
-15.40M
-15.29M
-14.34M
-10.28M
Net interest expenses
-10.80M
-10.16M
-10.48M
-6.39M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.69M
-41.71M
-58.54M
-48.94M
Gain or loss from assets sale
-
415.00K
334.00K
41.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps